393 related articles for article (PubMed ID: 28191756)
1. Aberrant Transforming Growth Factor-β Activation Recruits Mesenchymal Stem Cells During Prostatic Hyperplasia.
Wang L; Xie L; Tintani F; Xie H; Li C; Cui Z; Wan M; Zu X; Qi L; Cao X
Stem Cells Transl Med; 2017 Feb; 6(2):394-404. PubMed ID: 28191756
[TBL] [Abstract][Full Text] [Related]
2. Aberrant activation of TGF-β/ROCK1 enhances stemness during prostatic stromal hyperplasia.
Li Y; Li J; Zhou L; Wang Z; Jin L; Cao J; Xie H; Wang L
Cell Commun Signal; 2024 May; 22(1):257. PubMed ID: 38711089
[TBL] [Abstract][Full Text] [Related]
3. Transforming growth factor beta 1 and its receptor types I and II. Comparison in human normal prostate, benign prostatic hyperplasia, and prostatic carcinoma.
Royuela M; De Miguel MP; Bethencourt FR; Sanchez-Chapado M; Fraile B; Paniagua R
Growth Factors; 1998; 16(2):101-10. PubMed ID: 9932228
[TBL] [Abstract][Full Text] [Related]
4. MIR663AHG as a competitive endogenous RNA regulating TGF-β-induced epithelial proliferation and epithelial-mesenchymal transition in benign prostate hyperplasia.
Tong S; Mo M; Hu X; Wu L; Chen M; Zhao C
J Biochem Mol Toxicol; 2023 Sep; 37(9):e23391. PubMed ID: 37518988
[TBL] [Abstract][Full Text] [Related]
5. Aberrant TGF-β activation in bone tendon insertion induces enthesopathy-like disease.
Wang X; Xie L; Crane J; Zhen G; Li F; Yang P; Gao M; Deng R; Wang Y; Jia X; Fan C; Wan M; Cao X
J Clin Invest; 2018 Feb; 128(2):846-860. PubMed ID: 29355842
[TBL] [Abstract][Full Text] [Related]
6. Targeting stromal androgen receptor suppresses prolactin-driven benign prostatic hyperplasia (BPH).
Lai KP; Huang CK; Fang LY; Izumi K; Lo CW; Wood R; Kindblom J; Yeh S; Chang C
Mol Endocrinol; 2013 Oct; 27(10):1617-31. PubMed ID: 23893956
[TBL] [Abstract][Full Text] [Related]
7. Stromal cells of the human prostate: initial isolation and characterization.
Kassen A; Sutkowski DM; Ahn H; Sensibar JA; Kozlowski JM; Lee C
Prostate; 1996 Feb; 28(2):89-97. PubMed ID: 8604397
[TBL] [Abstract][Full Text] [Related]
8. Stromal transforming growth factor-beta signaling mediates prostatic response to androgen ablation by paracrine Wnt activity.
Placencio VR; Sharif-Afshar AR; Li X; Huang H; Uwamariya C; Neilson EG; Shen MM; Matusik RJ; Hayward SW; Bhowmick NA
Cancer Res; 2008 Jun; 68(12):4709-18. PubMed ID: 18559517
[TBL] [Abstract][Full Text] [Related]
9. Evidence of TGF-β1 mediated epithelial-mesenchymal transition in immortalized benign prostatic hyperplasia cells.
Hu S; Yu W; Lv TJ; Chang CS; Li X; Jin J
Mol Membr Biol; 2014; 31(2-3):103-10. PubMed ID: 24650126
[TBL] [Abstract][Full Text] [Related]
10. Tumor-promoting phenotype of CD90hi prostate cancer-associated fibroblasts.
Zhao H; Peehl DM
Prostate; 2009 Jun; 69(9):991-1000. PubMed ID: 19267366
[TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor-beta induces growth inhibition and IGF-binding protein-3 production in prostatic stromal cells: abnormalities in cells cultured from benign prostatic hyperplasia tissues.
Cohen P; Nunn SE; Peehl DM
J Endocrinol; 2000 Feb; 164(2):215-23. PubMed ID: 10657857
[TBL] [Abstract][Full Text] [Related]
12. Transforming growth factor-beta localization during mouse prostate morphogenesis and in prostatic growth abnormalities.
Timme TL; Yang G; Truong LD; Kadmon D; Park SH; Thompson TC
World J Urol; 1995; 13(6):324-8. PubMed ID: 9116750
[TBL] [Abstract][Full Text] [Related]
13. LPS/TLR4 Signaling Enhances TGF-β Response Through Downregulating BAMBI During Prostatic Hyperplasia.
He Y; Ou Z; Chen X; Zu X; Liu L; Li Y; Cao Z; Chen M; Chen Z; Chen H; Qi L; Wang L
Sci Rep; 2016 May; 6():27051. PubMed ID: 27243216
[TBL] [Abstract][Full Text] [Related]
14. Transforming growth factor beta 1 and androgen receptors in prostate neoplasia.
Cardillo MR; Petrangeli E; Salvatori L; Ravenna L; Di Silverio F
Anal Quant Cytol Histol; 2000 Oct; 22(5):403-10. PubMed ID: 11064817
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-18 may lead to benign prostatic hyperplasia via thrombospondin-1 production in prostatic smooth muscle cells.
Hamakawa T; Sasaki S; Shibata Y; Imura M; Kubota Y; Kojima Y; Kohri K
Prostate; 2014 May; 74(6):590-601. PubMed ID: 24615654
[TBL] [Abstract][Full Text] [Related]
16. Potential ameliorative effects of epigallocatechin‑3‑gallate against testosterone-induced benign prostatic hyperplasia and fibrosis in rats.
Zhou J; Lei Y; Chen J; Zhou X
Int Immunopharmacol; 2018 Nov; 64():162-169. PubMed ID: 30179845
[TBL] [Abstract][Full Text] [Related]
17. Antagonists of growth hormone-releasing hormone inhibit proliferation induced by inflammation in prostatic epithelial cells.
Popovics P; Schally AV; Salgueiro L; Kovacs K; Rick FG
Proc Natl Acad Sci U S A; 2017 Feb; 114(6):1359-1364. PubMed ID: 28123062
[TBL] [Abstract][Full Text] [Related]
18. Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium.
Ao M; Franco OE; Park D; Raman D; Williams K; Hayward SW
Cancer Res; 2007 May; 67(9):4244-53. PubMed ID: 17483336
[TBL] [Abstract][Full Text] [Related]
19. Elevated epithelial expression of interleukin-8 correlates with myofibroblast reactive stroma in benign prostatic hyperplasia.
Schauer IG; Ressler SJ; Tuxhorn JA; Dang TD; Rowley DR
Urology; 2008 Jul; 72(1):205-13. PubMed ID: 18314176
[TBL] [Abstract][Full Text] [Related]
20. Expression of transforming growth factor beta 1 (TGF beta 1), -beta 2, and- beta 3 by cultured human prostate cells.
Story MT; Hopp KA; Molter M
J Cell Physiol; 1996 Oct; 169(1):97-107. PubMed ID: 8841426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
